Myelofibrosis Post-polycythemia Vera

• CLINICAL_TRIALS research · 2026-03-19
  Clinical Trial Update: Study of Canakinumab in Patients With Myelofibrosis [Phase 2]

  A Phase 2 clinical trial evaluating canakinumab in patients with myelofibrosis is currently recruiting.

• CLINICAL_TRIALS research · 2026-02-25
  Clinical Trial Update: A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis [Phase 3]

  Phase 3 clinical trial update for pacritinib in primary myelofibrosis and myelofibrosis following polycythemia vera or essential thrombocyth…

• CLINICAL_TRIALS trial_result · 2025-12-23
  Clinical Trial Update: INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders [Phase 1, Phase 2]

  Clinical trial update shows INCB000928 is being studied as a monotherapy or in combination with ruxolitinib for anemia due to myeloprolifera…

• FDA approval · 2025-05-12
  FDA Approved: INREBIC — Supplemental Application (Celgene Corporation)

  The FDA approved a supplemental application for INREBIC (fedratinib hydrochloride) submitted by Celgene Corporation.

• CLINICAL_TRIALS trial_result · 2025-03-05
  Clinical Trial Update: Phase 2 Study in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly [Phase 2]

  Phase 2 study sponsored by Bristol-Myers Squibb in Japanese patients with intermediate-2 or high-risk primary myelofibrosis, post-polycythem…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.